Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Doxorubicin Market Outlook 2026-2030 & 2035: Predicted to Surge to $2 Billion by 2030, Bolstered by Expanding Access to Cancer Care

globenewswire.com
PFE Pfizer Inc. is mentioned as a major player in the doxorubicin market, investing in research for next-generation cancer therapies, indicating a neutral stance with moderate strength due to its involvement in a growing market. JNJ Johnson & Johnson's acquisition of Ambrx Biopharma for $2 billion to advance antibody-drug conjugates for prostate cancer shows a strong bullish sentiment, indicating significant investment and strategic focus on cancer therapies. BAX Baxter International Inc. is listed as a major player in the doxorubicin market, expanding its portfolios and investing in research, suggesting a neutral sentiment with moderate strength due to its participation in a growing sector. AMRX Ambrx Biopharma is mentioned as being acquired by Johnson & Johnson for $2 billion, indicating a strong bullish sentiment for the company due to the significant acquisition value and strategic importance in cancer therapy advancement.

Doxorubicin Market Outlook 2026-2030 & 2035: Predicted to Surge to $2 Billion by 2030, Bolstered by Expanding Access to Cancer Care Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Doxorubicin Market Report 2026" has been added to ResearchAndMarkets.com's offering.

This analysis provides a comprehensive perspective on the doxorubicin market, elucidating key trends, growth prospects, and the strategic actions of leading pharmaceutical firms. With a focus on innovation and expanding treatment coverage, the market is poised to address the increasing needs of the oncology sector effectively.

The doxorubicin market is experiencing robust growth, projecting an increase from $1.42 billion in 2025 to $2 billion by 2030, at a CAGR of 7.2%. This expansion is driven by rising cancer prevalence, enhanced clinical adoption of anthracyclines, and expanded hospital oncology infrastructure. Key factors fostering growth include rising demand for cost-effective oncology treatments and the evolution of liposomal and targeted drug delivery systems. Increased access to cancer therapies in developing regions and approvals of generic formulations further bolster this upward trajectory.

Doxorubicin is a key chemotherapeutic agent known for its efficacy in treating various cancer types. The drug's growing prominence is attributed to the increasing cancer incidence globally. In 2024, the American Cancer Society reports a projected rise to approximately 2 million new cancer cases in the U.S. alone, heightening the demand for doxorubicin-based treatments.

Leading pharmaceutical companies are focusing on innovation to enhance chemotherapy treatment efficacy, reduce adverse effects, and improve patient outcomes. Lupin Limited's introduction of Doxorubicin Hydrochloride Liposome Injection marks a significant step in advanced drug delivery systems, focusing on cancer types like advanced ovarian cancer and AIDS-related Kaposi's sarcoma. These innovations aim to improve targeted delivery and reduce systemic toxicity.

Strategic acquisitions are shaping the competitive landscape. Johnson & Johnson's acquisition of Ambrx Biopharma, valued at around $2 billion, underscores its commitment to advancing antibody-drug conjugates for prostate cancer.

The major players in the doxorubicin market include Pfizer Inc., Johnson & Johnson, Baxter International Inc., Teva Pharmaceutical Industries Ltd., among others. These companies are expanding their portfolios and investing in research to develop next-generation cancer therapies.

Regionally, North America led the market in 2025, with Asia-Pacific anticipated to be the fastest-growing region.

Reasons to Purchase:

Markets Covered: Drug formulations, applications, and distribution channels.

Key Companies: Includes Pfizer, Johnson and Johnson, Baxter International, and more.

Countries: Coverage of regions such as Australia, China, Germany, India, and the USA, among others.

Regions: Includes Asia-Pacific, Western Europe, North America, etc.

Time Series: Offers five-year historical data and ten-year forecast.

Data: Details on ratios, GDP correlations, and expenditure per capita.

Key Attributes

The companies featured in this Doxorubicin market report include:

For more information about this report visit https://www.researchandmarkets.com/r/tksg1c

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment